Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer [Yahoo! Finance]
Uremic Pruritus Pipeline Insight 2024, Featuring Key Players Cara Therapuetics and Lumosa Therapeutics, and Key Emerging Drugs Cara Therapeutics CR845 and Lumos Therapeutics' LT 5001 [Yahoo! Finance]
Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference